脂质体阿霉素在妇科肿瘤中的临床应用
作者：李克敏;尹如铁;谢丹;
Author：
收稿日期： 年卷（期）页码：2013,28(05):-545-547
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：脂质体阿霉素;妇科肿瘤;经济学
Key words：
基金项目：四川省科技厅支撑项目(编号:0040215301165)
中文摘要
脂质体阿霉素的治疗效果较阿霉素更佳,且具有制备简单、对机体无毒、无免疫原性及易实现靶向性等优点。现综述其在妇科肿瘤中的应用及其卫生经济学研究。
参考文献
[1]Gupta PK,Hung CT,Rao NS.Ultrastructure disposition of adria-mycin associated magnetic albumin microspheres in rats[J].JPharm Sci,1989,78(4):299-294.
[2]Batist G,Barton J,Chaikin P.Myocet(liposome-encapsulateddoxorubicin citrate):A new approach in breast cancer therapy[J].Expert Opin Pharmacother,2002,3(12):1739-1751.
[3]Poivier VJ,Thamm DH,Kurzma ID,et al.Liposomeiencapsulateddoxorubicin(doxil)and doxorubicin in the treament of vaccine-associated sarcoma in rat[J].J Vet Intern Med,2002,16(6):726-731.
[4]王汝兴,张宇丽.脂质体的研究进展及制备方法[J].承德医学院学报,2008,25(2):183-185.
[5]张俭俭,孙晓东.新型脂质体的应用研究进展[J].中国药房,2007,18(31):2465-2466.
[6]Gabizon AA.Characterization and cytotoxicity of mixed PEG-DSG modified liposomes[J].Yakugaku Zasshi,2005,125(1):149-157.
[7]Sadava D,Coleman A,Kane SE.Liposomal daunorubiein overeomesdrug resistance in human breast,ovarian and lung carcinoma cells[J].J Liposome Res,2002,12(4):301-309.
[8]Gokhale PC,Radhadhakrlshnan B,Husain SR,et al.An improvedmethod of encapsulation of doxorubicin in liposomes:Pharmaco-logical,loxicological,and therapeutic evaluation[J].Br J Cancer,1996,56:3743-3746.
[9]Guo HY,Nelson N.Combined oral thalidomide with liposom aldo-xorubicin in the treatment of recurrent epithelial ovarian and pri-mary peritoneal cancers[J].Prog Obstet Gynecol,2008,17(2):109-112.
[10]Tambaro R,Greggi S.An escalating dose finding study of liposom-al doxorubicin and vinorelbine for the treatment ofrefractory orresistant epithelial ovarian cancer[J].Gynecologic tumors,2003,14(9):1406-1411.
[11]Katsaros D,Oletti MV,Rigault de la,et al.Clinical and pharma-cokinetic phaseⅡstudy of pegylated liposomal doxorubicin andvinorelbine in heavily pretreated recurrent ovarian carcinoma[J].Annals Oncology,2005,16(2):300-306.
[12]裴海英,方芳.托泊替康治疗复发性卵巢癌的系统评价[J].中国循证医学杂,2006,6(10):733-742.
[13]Ferrero JM,Weber B,Geay JF,et al.Second-line chemotherapywith pegylated liposomal doxorubicin and carboplatin is highlyeffective in patients with advanced ovarian cancer in late relapse:A GINECO phaseⅡtrial[J].Annals Oncology,2007,18(2):263-268.
[14]Petru E,Angleitmer-Boubenizek L,Reinthaller A,et al.Com-bined PEG liposomal doxorubicin and gemcitabine are active andhave acceptable toxicity in patients with platinum-refractory andresistant ovarian cancer after previous platium-taxane therapy:AphaseⅡAustrian AGO study[J].Gynecol Oncol,2006,102(2):226-229.
[15]Recchia,France scoa,Filippis,et al.PhaseⅠstudy of liposomaldoxorubicin andoxaliplatin as salvage chemotherapy in advancedovarian cancer[J].Anti Cancer Drug,2003,14(8):633-638.
[16]Homesley HD,Blessing JA,Sorosky J,et al.PhaseⅡtrial of lipo-somal doxorubicin at 40mg/m2 every 4 weeks in endometrial car-cinoma:A gynecologic oncology group study[J].Gynecol Oncol,2005,98(2):294-298.
[17]Sutton G,Blessing J,Haniani P,et al.PhaseⅡevaluation of lipo-somal doxrubicin(Doxil)-in recurrent or advanced leiomyosar-coma of the uterus:A gynecologic oncology group study[J].Gynecol Oncol,2005,96(3):749-752.
[18]Pignata S,Scambia G.Safety of a 3-weekly schedule of carbopl-atin plus pegylated liposomal doxorubicin as first line chemothera-py in patients with ovarian cancer:Preliminary results of the MI-TO-2 randomized trial[J].BMC Cancer,2006,Aug1(6):202.
[19]Smith DH,Adams JR,Johnston SR,et al.A comparative economicanalysis of pegylated liposomal doxorubicin versus topotecan in o-varian cancer in the USA and the UK[J].Annals Oncology,2002,13(10):1590-1597.
[20]Main C,Bojke L,Griffin S,et al.Topotecan,pegylated liposomaldoxorubicin hydrochloride and paclitaxel for second-line or sub-sequent treatment of advanced ovarian cancer:A systematic reviewand economic evaluation[J].Health Technol Assess,2006,10(9):1-132.
【关闭】
